Precision Biosciences Inc
DTIL
Get informed when a big investor buys or sells
+ FollowMarket Cap$185.48M
Close$
$16.72
171% upside
Current Fair Value
171% upsideUndervalued by 171% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $185.48 Million |
|---|---|
| Enterprise Value | $101.01 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.56 |
| Beta | 1.28 |
| Outstanding Shares | 25,856,628 |
Return
| Return on Equity | -116.42% |
|---|---|
| Return on Assets | -41.88% |
| Return on Invested Capital | -38.08% |
Valuation & Multiples
| P/E Ratio | -2.41 |
|---|---|
| PEG | -6.2 |
| Price to Sales | 6.17 |
| Price to Book Ratio | 6.17 |
| Enterprise Value to Revenue | 2.24 |
| Enterprise Value to EBIT | -2.23 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.80
Average shareholder expectationRevenue Estimate
$740,000
Average shareholder expectationNext Earnings Call
Expected Date
November 2, 2026
EPS Estimate
$-0.85
Average shareholder expectationRevenue Estimate
$1.38 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.2019▲ 120.19% |
|---|---|
| Total Calls | 10,400▼ 49.02% |
| Total Puts | 12,500▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 68.82%▲ 3.26% |
|---|---|
| Total Invested | $139.67M▲ 58.51% |
| Investors Holding | 98▲ 20.00% |
ESG Score
No data
About Precision Biosciences Inc
CEO: Matthew Kane